Molecular Formula | C20H16N6O |
Molar Mass | 356.38 |
Density | 1.51±0.1 g/cm3(Predicted) |
Boling Point | 775.5±55.0 °C(Predicted) |
Solubility | DMSO: ≥ 31mg/mL |
pKa | 10.51±0.10(Predicted) |
Storage Condition | -20℃ |
In vitro study | In cellular level assays, CH5183284 at 100 to 300 nM prevented DMS114 (FGFR1 amplification),SNU-16 (FGFR2 amplification), and KMS11 [t(4;14) translocation and FGFR3 Y373C mutation] autophosphorylation of FGFR1,FGFR2, and FGFR3 in cell lines. CH5183284 thus produces selective anti-proliferative activity against cancer cell lines comprising genetic alterations of FGFR. FGFR2 contains a gating mutation (V564F) that makes it resistant to other FGFR inhibitors, while CH5183284 can inhibit it. |
In vivo study | CH5183284 (100 mg/kg/day, p.o.) xenografts with genetically altered FGFR, such as KG1 (leukemia, FGFR1OP-FGFR1 fusion),SNU-16 (gastric cancer, FGFR2 amplification),MFE-280 (endometrial cancer, FGFR2 S252W mutant),UM-UC-14 (bladder cancer, FGFR3 S249C mutant), and RT112/84 (bladder cancer, FGFR3-TACC3 fusion) produced significant selective antitumor activity. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.806 ml | 14.03 ml | 28.06 ml |
5 mM | 0.561 ml | 2.806 ml | 5.612 ml |
10 mM | 0.281 ml | 1.403 ml | 2.806 ml |
5 mM | 0.056 ml | 0.281 ml | 0.561 ml |
biological activity | CH5183284 is a selective, orally effective FGFR inhibitor for FGFR1,FGFR2,FGFR3, and FGFR4 IC50 were 9.3 nM,7.6 nM,22 nM, and 290 nM, respectively. Phase 1. CH5183284 (Debio-1347, FF284) is a selective orally potent FGFR inhibitor with IC50 of 9.3 nM,7.6 nM for FGFR1,FGFR2,FGFR3, and FGFR4, respectively, 22 nM, and 290 nM. Phase 1. |
Target | Value |
FGFR2 (Cell-free assay) | 7.6 nM |
FGFR1 (Cell-free assay) | 9.3 nM |
FGFR3 (Cell-free assay) | 22 nM |
FGFR4 (Cell-free assay) | 290 nM |